Related Experiment Video
Updated: Jan 31, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Comparative Therapeutic Assessment of Atrial Fibrillation in Heart Failure With Reduced Ejection Fraction-A Network
Aaqib H Malik1, Wilbert S Aronow
1Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.
Insights
Catheter ablation (CA) significantly reduces mortality and heart failure hospitalizations in atrial fibrillation (AF) patients with reduced ejection fraction (HFrEF). CA also improves heart function and quality of life, supporting its use as a first-line therapy.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Atrial fibrillation (AF) management in heart failure with reduced ejection fraction (HFrEF) remains challenging.
- Catheter ablation (CA) is emerging as a potential first-line strategy for these patients.
Purpose of the Study:
- To compare the effectiveness of CA versus optimal medical treatment and anti-arrhythmic drugs for AF in HFrEF patients.
- To evaluate CA's impact on mortality, heart failure hospitalizations, and cardiac function.
Main Methods:
- Network meta-analysis of 17 randomized controlled trials (RCTs) involving 5460 participants.
- Included treatments: CA, optimal medical therapy, anti-arrhythmic drugs, and placebo.
- Primary outcomes: all-cause mortality, heart failure hospitalization, and left ventricular ejection fraction (LVEF) change.
Main Results:
- CA significantly reduced all-cause mortality (OR 0.44) and heart failure hospitalizations (OR 0.41) compared to optimal medical therapy.
- CA improved LVEF (OR 9.34), quality of life (Minnesota Living with Heart Failure Questionnaire score reduction), and 6-minute walking distance (6MWT).
Conclusions:
- Catheter ablation is the most effective and safe treatment for AF patients with HFrEF.
- CA should be considered a first-line therapy for managing AF in this patient population.
Background:
Catheter ablation (CA) continues to prove to be an intriguing therapeutic option for the management of atrial fibrillation (AF) especially in patients with heart failure with reduced ejection fraction (HFrEF). Recent data have suggested that CA may be a viable first-line strategy for these patients.
Study Question:
Is CA more effective in managing patients with AF with HFrEF compared to optimal medical treatment and anti-arrhythmic drugs?
Data Sources:
Randomized controlled trials (RCTs) comparing CA, medical treatment, or antiarrhythmic drugs to each other or a placebo group for the treatment of AF in HFrEF. We performed a comprehensive search in PubMed, Embase, and Cochrane library to identify relevant RCTs.
Study Design:
Our primary outcomes of interest were all-cause mortality, hospitalization for heart failure, and the percentage change in left ventricular ejection fraction. Also, we looked at functional outcomes such as Minnesota Living with Heart Failure Questionnaire and 6-minute walking distance. We used event rates for categorical variables and mean differences between the groups for the continuous variables. We used a frequentist approach employing a graph theory methodology to construct a network meta-analysis model.
Results:
We ended up with 17 RCTs with 5460 participants and 5 different treatments in our network meta-analysis. Compared to optimal medical therapy, CA was effective in reducing all-cause mortality odds ratio (OR) 0.44 (95% confidence interval, 0.27-0.74; P-value: <0.001) and hospitalization for heart failure OR 0.41 (0.28-0.59; P-value: <0.001). CA also resulted in improvement in left ventricular ejection fraction OR 9.34 (7.13-11.55; P-value: <0.001), Minnesota Living with Heart Failure Questionnaire OR -7.75 (-13.98 to -1.52; P-value: <0.01), and 6MWT OR 27.30 (5.27-49.33; P-value: <0.02).
Conclusions:
CA is the most effective and safe treatment for AF patients with HFrEF. We should consider this as a first-line therapy for the management of these patients.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Heart Failure Drugs: Diuretics

